Welcome to our dedicated page for iRhythm Technologies news (Ticker: $IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iRhythm Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iRhythm Technologies's position in the market.
iRhythm Technologies, a digital healthcare company, reported first quarter 2024 financial results with revenue of $131.9 million, an 18.4% increase from last year. Gross margin was 66.3% with cash reserves of $569.1 million. They increased their fiscal year 2024 revenue guidance to $578-$588 million. Operational highlights included over half a million registrations and collaborations to drive efficiencies. The CEO highlighted strong revenue growth, increased traction in primary care, and the potential of EKG data for clinical insights.